The historical rank and industry rank for PDL BioPharma's Price-to-Tangible-Book or its related term are showing as below:
PDLI's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68 * Ranked among companies with meaningful Price-to-Tangible-Book only.
PDL BioPharma Price-to-Tangible-Book Historical Data
The historical data trend for PDL BioPharma's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PDL BioPharma's Price-to-Tangible-Book
For the Biotechnology subindustry, PDL BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDL BioPharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDL BioPharma's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where PDL BioPharma's Price-to-Tangible-Book falls into.
PDL BioPharma Price-to-Tangible-Book Calculation
PDL BioPharma's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
PDL BioPharma Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of PDL BioPharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
PDL BioPharma (PDL BioPharma) Business Description
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PDLI has been successfully added to your 